Tiong, Mark K.
Cai, Michael M. X.
Toussaint, Nigel D.
Tan, Sven-Jean
Pasch, Andreas
Smith, Edward R.
Funding for this research was provided by:
Royal Melbourne Hospital Research Funding Program Grant in Aid (Grant number 2018.036)
Article History
Received: 23 February 2022
Accepted: 31 March 2022
First Online: 5 May 2022
Competing interests
: M.K.T. and M.M.X.C. report no competing interests. N.D.T. reports research funding and honoraria from Amgen, Sanofi and Takeda. S.J.T. reports honoraria from AstraZeneca. A.P. is an inventor of the T50 test and a stockholder of Calciscon AG (Biel, Switzerland), which commercialises the test used in this study. E.R.S. is a stockholder of Calciscon AG (Biel, Switzerland), which commercialises the T50 test used in this study. He also reports research funding from Sanofi and Baxter.